CSL Limited
Australian multinational biotechnology company specializing in plasma-derived medicines, vaccines, and other products for serious medical conditions.
Last updated October 14, 2026
AI crawler reads
5requests
1companies- Anthropic5
- Profile
- 3
- Controversies
- 2
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
CSL Limited is an Australian multinational biotechnology company whose principal activities are the research, development, manufacture, and marketing of specialized medicines and vaccines. Its business is organized around products derived from human blood plasma, influenza and other vaccines, specialty pharmaceuticals, and therapies for immune, bleeding, respiratory, renal, and other serious conditions. The company also produces antivenoms and selected products used in biomedical research and biomanufacturing. The organization began in 1916 as Commonwealth Serum Laboratories, an Australian government laboratory established to improve the domestic supply of vaccines and other biological products. It started operations in Melbourne in 1918 and moved to purpose-built facilities at Parkville in 1919. During its early decades, CSL manufactured insulin, vaccines, antivenoms, immunoglobulins, and other products that had previously been difficult to obtain in Australia. Its history includes important public-health work, but also the 1928 Bundaberg tragedy, in which a diphtheria toxin-antitoxin product manufactured by CSL was associated with the deaths of twelve children. Investigations did not attribute the deaths to the laboratory's manufacturing process, but identified labeling failures, contributing to a lasting emphasis on quality control and product safety. CSL expanded its scientific and manufacturing capabilities through work on antivenoms, penicillin, plasma fractionation, blood products, and vaccines. Plasma fractionation began in 1952, creating the foundation for the modern plasma-products business. Later achievements included tetanus and combination vaccines, polio-vaccine production, Rhesus immunoglobulin, and heat-treatment methods intended to reduce the risk of infectious transmission from blood and plasma products. CSL also contributed to the development of Gardasil through collaboration involving Australian researcher Ian Frazer and other partners. The company was privatized by the Australian government in 1994 and listed on the Australian Securities Exchange. Its international scale increased substantially through the acquisition of ZLB Bioplasma in 2000 and Aventis Behring in 2004. These transactions created the basis for CSL Behring, the group's major plasma-derived and specialty-biologics business. CSL subsequently expanded its vaccines business by acquiring Novartis's global influenza-vaccine business in 2015 and combining it with BioCSL under the Seqirus name. The group later acquired Calimmune's stem-cell-therapy platform and Vitaeris, and agreed to acquire Vifor Pharma, strengthening its specialty-pharmaceutical and renal-care portfolio. CSL's principal operating businesses are CSL Behring, CSL Plasma, CSL Seqirus, and CSL Vifor. CSL Behring develops plasma-derived and recombinant therapies for immune deficiencies, bleeding disorders, hereditary angioedema, respiratory disease, and critical-care applications. CSL Plasma operates a large international network of plasma-collection centers that supplies fractionation operations. CSL Seqirus is a major influenza-vaccine producer and also supplies selected travel, pandemic, and specialty vaccines, as well as Australian antivenoms. CSL Vifor focuses on medicines for iron deficiency, kidney disease, dialysis-related care, and related specialty conditions. The company retained a prominent role in Australia's response to the COVID-19 pandemic. In 2020, it entered agreements concerning manufacture of the Oxford-AstraZeneca vaccine and supply of the University of Queensland vaccine candidate. The Queensland candidate was discontinued after trial participants produced false-positive HIV test results. CSL subsequently manufactured Oxford-AstraZeneca doses at its Broadmeadows facility for the Australian government. Today, CSL remains headquartered in Melbourne and operates research, manufacturing, plasma-collection, and commercial facilities across Australia, the Unite…
History
CSL was established in 1916 as Commonwealth Serum Laboratories, a body of the Australian government created to develop and manufacture vaccines and other biological products for domestic use. It began operating in Melbourne in 1918 in premises associated with the Walter and Eliza Hall Institute and moved to a purpose-built Parkville site the following year. Under its first director, William Penfold, the laboratory developed production capabilities for vaccines, insulin, antitoxins, and other medical products. The institution faced a major crisis in 1928 when a diphtheria toxin-antitoxin batch was connected with the deaths of twelve children in Bundaberg, Queensland. Reviews concluded that the manufacturing process itself had not caused the contamination, but found that labeling procedures were inadequate. The event became a defining lesson in biological-product regulation and safety. During the same period, CSL began systematic antivenom work with researchers associated with the Walter and Eliza Hall Institute. Antivenom for tiger-snake bites was clinically tested in 1930 and commercially released in 1931. Research later expanded to antivenoms for additional snakes, spiders, marine animals, and other Australian hazards. CSL developed further biological-manufacturing capacity during the 1930s and 1940s. Its scientists worked on influenza and polio research with external collaborators, and the organization began producing penicillin in 1944, an important wartime contribution. It also produced insulin for Australian patients, introduced tetanus vaccination, and developed combination vaccines against diphtheria, tetanus, and whooping cough. In 1952, CSL began plasma fractionation. This enabled the production of albumin, immunoglobulins, clotting factors, and related blood-derived therapies and gradually shifted the institution toward the specialty-biotechnology model it retains today. During the 1950s and 1960s, CSL expanded its vaccine, antivenom, and blood-products portfolio. It adopted polio-vaccine production, created polyvalent antivenoms, and developed Rhesus immunoglobulin to reduce the risk of hemolytic disease in newborns. Later, the company pioneered heat-treatment approaches for blood and plasma products designed to reduce infectious risks, including HIV transmission. CSL also participated in the broader scientific and commercial development of human papillomavirus vaccination, which ultimately contributed to Gardasil. The Australian government privatized CSL in 1994. The company was converted into CSL Limited and listed on the Australian Securities Exchange through an initial public offering. International expansion accelerated in 2000 when CSL acquired Swiss plasma company ZLB Bioplasma AG. In 2004 it purchased Aventis Behring, a German-based medical-products business. The combined operations became the foundation of CSL Behring and gave CSL a much larger global plasma-collection, fractionation, and specialty-therapeutics platform. CSL continued to broaden its vaccine activities. In 2014, Novartis announced the sale of its influenza-vaccine business to CSL, and the transaction was completed in 2015. The acquired business was combined with BioCSL and rebranded Seqirus, creating one of the world's largest influenza-vaccine companies. CSL later acquired Calimmune's stem-cell-therapy platform and announced the acquisition of Vitaeris. In 2021, it agreed to acquire Vifor Pharma, adding a substantial specialty-pharmaceutical business focused particularly on iron deficiency and kidney disease. The transaction led to the formation of CSL Vifor within the group's operating structure. During the COVID-19 pandemic, CSL entered agreements with the Australian government relating to both the University of Queensland vaccine candidate and manufacture of the Oxford-AstraZeneca vaccine. The Queensland candidate was abandoned after vaccine-induced antibodies caused false-positive HIV test results in trial participants. CSL nevertheless proceeded with domestic production of Oxford-AstraZeneca vaccine, with the first batches receiving provisional approval in March 2021. In 2022, the company aligned its divisional identities under the CSL master brand. Its current businesses encompass plasma collection, plasma-derived and recombinant therapies, vaccines, antivenoms, and specialty pharmaceuticals, supported by facilities and commercial operations across Australia, the United States, Europe, and other markets.
- 2022
Operating divisions unified under CSL master brand
[1]The group's divisions are renamed CSL Behring, CSL Plasma, CSL Seqirus, and CSL Vifor.
- 2021
Australian production of Oxford-AstraZeneca vaccine approved
[1]Australia's regulator provisionally approves initial Oxford-AstraZeneca COVID-19 vaccine batches manufactured by CSL.
- 2015
Seqirus created
[1]CSL combines its BioCSL vaccine activities with Novartis's acquired influenza-vaccine business and launches the Seqirus brand.
- 2004
Aventis Behring acquired
[1]CSL acquires Aventis Behring, expanding its plasma-derived and specialty-biologics operations.
- 2000
ZLB Bioplasma acquired
[1]CSL acquires Swiss plasma company ZLB Bioplasma AG, materially increasing its international scale.
- 1994
Privatization and ASX listing
[1]The Australian government privatizes CSL, which becomes CSL Limited and is listed on the Australian Securities Exchange.
- 1952
Plasma fractionation begins
[1]The company commences plasma fractionation, establishing the technical basis for its modern plasma-derived medicines business.
- 1944
Penicillin production begins
[1]CSL begins producing penicillin during the Second World War.
- 1931
Commercial tiger-snake antivenom released
[1]Following clinical testing, CSL commercially releases antivenom for tiger-snake envenomation.
- 1918
Operations begin in Melbourne
[1]CSL begins operating in Melbourne in premises associated with the Walter and Eliza Hall Institute.
Products and positioning
Specialty biotechnology and biopharmaceutical group focused on plasma-derived therapies, vaccines, and medicines for serious and rare diseases.
Plasma-derived medicines
CSL Behring plasma-derived therapies
CSL Behring supplies immunoglobulins, albumin, coagulation factors, fibrinogen, antithrombin, C1-esterase inhibitor, and other plasma-derived products. These therapies are used in primary and secondary immune deficiencies, hemophilia and other bleeding disorders, hereditary angioedema, critical care, and replacement of specific plasma proteins. Representative brands include Privigen, Hizentra, Berinert, Humate-P, Rhophylac, and Albumin products. Availability and formulation vary by country.
Vaccines
CSL Seqirus influenza vaccines
CSL Seqirus develops and manufactures seasonal influenza vaccines for different age groups and markets. Its portfolio has included Afluria and Afluria Quadrivalent, Fluad and Fluad Quadrivalent, and cell-based or adjuvanted influenza products marketed under different names according to national registration. Seqirus also maintains pandemic-influenza capabilities and supplies vaccines internationally.
Antivenoms · 1931
Australian antivenoms
CSL's antivenom portfolio covers medically important Australian snakes, spiders, and marine animals. Products have included tiger-snake, taipan, brown-snake, death-adder, funnel-web-spider, redback-spider, stonefish, sea-snake, and box-jellyfish antivenoms, together with polyvalent snake antivenom and the Snake Venom Detection Kit. These products originated in the laboratory's long-standing Australian venom-research program.
Vaccine
Q-VAX
Q-VAX is a vaccine against Q fever caused by Coxiella burnetii. It has been used in Australia for people whose occupations or activities create elevated exposure risk, subject to applicable medical screening and regulatory requirements.
Specialty pharmaceuticals · 2022
CSL Vifor specialty medicines
CSL Vifor extends the group into specialty pharmaceuticals, particularly treatments for iron deficiency, anemia associated with kidney disease, and conditions managed in nephrology and dialysis settings. The business joined CSL following the acquisition of Vifor Pharma and complements the group's existing biologics and hospital-care activities.
Controversies
2010
Investigation of febrile convulsions after H1N1 vaccination
Australian authorities investigated febrile convulsions reported in children after administration of CSL's Panvax and Panvax Junior pandemic H1N1 vaccines. Scientific publications proposed that a manufacturing-process factor might have contributed, although the event is best described as a regulatory and vaccine-safety investigation rather than a finding of intentional misconduct.
1928
Bundaberg diphtheria tragedy
A diphtheria toxin-antitoxin batch associated with CSL was linked to the deaths of twelve children in Bundaberg, Queensland. Investigations did not find that the manufacturing process caused the deaths, but identified labeling failures. The incident became a major historical lesson in biological-product safety and quality control.
Brand decisions
2021
Acquire Vifor PharmaM&ABackground
CSL sought to diversify beyond plasma products and vaccines into specialty pharmaceuticals, particularly renal and iron-deficiency care.
Action taken
CSL announced an agreement to acquire Swiss pharmaceutical company Vifor Pharma.
Aftermath
Vifor became CSL Vifor and added specialty medicines and a substantial nephrology-focused commercial platform.
Announced transaction value. US$11.7 billion (December 2021 announcement)
2020
Support COVID-19 vaccine development and manufactureProduct launchBackground
Australia sought domestic access to COVID-19 vaccines and local manufacturing capacity during the pandemic.
Action taken
CSL signed agreements concerning the University of Queensland vaccine candidate and manufacture of the Oxford-AstraZeneca vaccine.
Aftermath
The University of Queensland candidate was discontinued after false-positive HIV test results, while CSL proceeded with Australian production of Oxford-AstraZeneca vaccine.
2015
Combine BioCSL with Novartis influenza vaccinesM&ABackground
CSL wanted to build a larger global influenza-vaccine platform.
Action taken
CSL acquired Novartis's influenza-vaccine business and combined it with BioCSL under the Seqirus name.
Aftermath
Seqirus became a major international influenza-vaccine business within CSL.
Acquisition consideration. A$275 million (2014 announcement)
2004
Acquire Aventis BehringM&ABackground
CSL aimed to extend its plasma-products and specialty-medical operations beyond Australia.
Action taken
The company acquired Aventis Behring and integrated the business into the CSL group.
Aftermath
The enlarged business became the foundation of CSL Behring and strengthened CSL's position in therapies for immune and bleeding disorders.
2000
Acquire ZLB BioplasmaM&ABackground
CSL sought greater international scale in plasma collection, fractionation, and plasma-derived medicines.
Action taken
CSL acquired Swiss plasma company ZLB Bioplasma AG.
Aftermath
The acquisition substantially expanded CSL's plasma business and international operating base.
1994
Proceed with privatization and public listingStrategyBackground
CSL had operated as an Australian government laboratory since its creation.
Action taken
The government privatized the organization as CSL Limited and listed it on the Australian Securities Exchange.
Aftermath
The listing provided a platform for international acquisitions and the transformation of CSL into a global biotechnology group.
Recent events
Reported
CSL appoints Deborah Waterhouse as CEO and Managing Director[2]
CSL announced that it had appointed Deborah Waterhouse as Chief Executive Officer and Managing Director, with the appointment to take effect on 1 February 2027. Gordon Naylor will continue as Interim CEO and Managing Director until then.
- Unconfirmed
UniQuest partners with CSL to advance potential therapy development[3]
UniQuest partnered with CSL to accelerate development of a potential treatment for blood vessels damaged by inflammation. The technology is to advance to pre-clinical studies with $500,000 from CSL's Research Acceleration Initiative.
- Unconfirmed
Reported
CSL and Takeda join forces to develop a COVID-19 plasma treatment[4]
CSL joined forces with Takeda to develop a COVID-19 plasma treatment using antibodies from recovered patients to help seriously ill people.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/csl-limited · Editorial policy · How profiles are compiled